Amicus Therapeutics (NASDAQ:FOLD) Receives “Overweight” Rating from Cantor Fitzgerald

Amicus Therapeutics (NASDAQ:FOLD)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $21.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 124.36% from the stock’s current price.

FOLD has been the topic of a number of other reports. JPMorgan Chase & Co. lifted their price objective on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 12th. Guggenheim lifted their target price on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. StockNews.com downgraded shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Morgan Stanley reissued an “equal weight” rating and issued a $12.00 target price (down previously from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Finally, Bank of America boosted their price objective on shares of Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, October 17th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Amicus Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $16.88.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $9.36 on Wednesday. The firm has a market cap of $2.80 billion, a PE ratio of -27.53, a price-to-earnings-growth ratio of 1.25 and a beta of 0.62. Amicus Therapeutics has a fifty-two week low of $8.78 and a fifty-two week high of $14.03. The company has a debt-to-equity ratio of 2.18, a quick ratio of 2.42 and a current ratio of 3.15. The business has a 50 day moving average price of $9.77 and a 200-day moving average price of $10.53.

Insider Activity

In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,901 shares of the stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $11,083,175. This represents a 0.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 22,901 shares of company stock valued at $259,863 in the last ninety days. Corporate insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Envestnet Asset Management Inc. lifted its position in shares of Amicus Therapeutics by 3.7% in the second quarter. Envestnet Asset Management Inc. now owns 450,823 shares of the biopharmaceutical company’s stock worth $4,472,000 after buying an additional 16,263 shares in the last quarter. Massachusetts Financial Services Co. MA raised its holdings in shares of Amicus Therapeutics by 14.3% in the second quarter. Massachusetts Financial Services Co. MA now owns 3,020,536 shares of the biopharmaceutical company’s stock worth $29,964,000 after buying an additional 378,999 shares during the period. Mutual of America Capital Management LLC increased its stake in Amicus Therapeutics by 24.2% in the second quarter. Mutual of America Capital Management LLC now owns 250,293 shares of the biopharmaceutical company’s stock worth $2,483,000 after purchasing an additional 48,802 shares during the period. Blair William & Co. IL lifted its holdings in Amicus Therapeutics by 15.2% during the 2nd quarter. Blair William & Co. IL now owns 47,254 shares of the biopharmaceutical company’s stock valued at $469,000 after buying an additional 6,237 shares in the last quarter. Finally, Inspire Investing LLC raised its stake in shares of Amicus Therapeutics by 13.3% during the second quarter. Inspire Investing LLC now owns 35,242 shares of the biopharmaceutical company’s stock valued at $350,000 after acquiring an additional 4,148 shares in the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.